News stories about ANI Pharmaceuticals (NASDAQ:ANIP) have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.4353064638603 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 1.18% on Monday, reaching $50.68. 18,605 shares of the company were exchanged. The firm has a market capitalization of $589.81 million, a PE ratio of 110.90 and a beta of 3.10. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $69.85. The stock’s 50-day moving average is $46.71 and its 200 day moving average is $47.94.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.19. The company had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The business’s quarterly revenue was up 43.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.11 earnings per share. On average, analysts forecast that ANI Pharmaceuticals will post $3.84 EPS for the current year.

A number of research analysts recently issued reports on ANIP shares. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 9th. Guggenheim reiterated a “buy” rating and issued a $80.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. ANI Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $65.33.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/18/ani-pharmaceuticals-anip-earns-coverage-optimism-score-of-0-21.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.